Narrative review / 2014
An analysis suggests the FDA's proposed ban on artificial trans fats provides public health gains at low to no cost and is economically sensible.
This commentary compared the benefits and costs of the US Food and Drug Administration's proposed ban on artificial trans fats against other public health risks and interventions. It assessed population disease burden, individual mortality risks, and cost-effectiveness per quality-adjusted life-year (QALY) gained. The population impact of remaining trans fats was small relative to many other risks, but lifetime individual risks were comparable to other notable risks. The ban was found to achieve public health gains at low to no cost, making it sensible from an economic efficiency perspective.
- Study type
- Economic and risk analysis commentary
- Who was studied
- US population
- What was measured
- Population disease burden (QALYs), individual mortality risks, cost-effectiveness
THE PAPER
FDA's proposed ban on trans fats: How do the costs and benefits stack up?
Cohen JT. Clin Ther, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.